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ABSTRACT 
 
 
Joshi, Kaushal .M.S., Department of Pharmacology and Toxicology, Wright State 
University, 2009. 
NOVEL NEUROPROTECTANTS FOR SARIN PLUS CBDP INDUCED 
CONVULSIONS. 
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Sarin,  also  known  as  Sarin  (German agent B)  is  classified  as  a  weapon  of  mass 
destruction.  Sarin (O-isopropyl methyl phosphonofluoridate) is a highly toxic nerve 
agent originally produced for chemical warfare and has been used in terrorist activities.  
Sarin is an extremely potent acetylcholinesterase inhibitor with high specificity and 
affinity for the enzyme.  High sarin doses causes death due to anoxia resulting from 
airway obstruction, weakness of the muscles of respiration, respiratory failure and 
convulsions.  Current treatments are still not effective at protecting against long term 
effects following exposure.  A current approach aims to counteract the increased 
glutamatergic and cholinergic neurotransmission occurring in sarin neurotoxicity.  In 
vitro and in vivo, serotonin (5-HT) 1A agonist prevented toxicity from glutamate.  We 
determined the neuroprotective capabilities of serotonin (5-HT) 1A agonists as novel 
pharmacological countermeasures to chemical warfare agents.  Rodents have higher 
amount of carboxylesterase enzyme and requires higher doses of sarin than other species.  
To address this issue we administered 1.5 mg/kg of CBDP (2-/o-cresyl/-4 H-1: 3: 2-
benzodioxa-phosphorin-2-oxide), which specifically blocks carboxyl esterase and makes 
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mouse model comparable to that of human exposure.  We determined 1mg/kg dose of 
serotonin (5-HT) 1A agonists 8-OH-DPAT from dose response curve based on 
neuroprotection, with toxic challenge of 1.5 mg/kg CBDP and dose of sarin yielding 25-
50 % mortality.  This mortality rate gave enough number of survivors with seizures and 
neurodegeneration for reliable baselines.  Measurements were mortality, weight loss 
AChE activity in blood and CNS, functional observational battery (FOB) and histology 
compared to control and toxic challenge mice.  In addition, a time response curve after 
toxic challenge was determined with 1mg/kg of 8-OH-DPAT at time points of 1, 15, 30, 
45, 60 minutes and 2, 4, 6 hours.  We observed neuroprotection by 8-OH-DPAT in the 
dentate gyrus of the hippocampus when administered up to two hours after Sarin.  The 
ability of the combination of serotonin (5-HT) 1A agonist’s dose and time after toxic 
challenge was tested for its ability to reinstate fear potentiated startle (FPS) response.  
However this test was invalidated by the response of the control group.  DPAT like drugs 
could be useful in treatment of long term effects produced by sarin induced convulsions.  
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Introduction  
Organophosphate nerve agents and its history 
The organophosphate (OPs) nerve agents are one of the most toxic chemical warfare 
agents developed in the 20
th
 century.  The first nerve warfare agents were produced by 
Nazi Germany during World War II.  The first was tabun (GA-German agent A) and 
second was sarin (Sarin-German agent B) known as G-type agents.  These nerve agents 
were weaponized and stocked by Germany, but there have been some debates over use of 
these weapons in World War II.  The first confirmed use of nerve agents in warfare was 
Iraq’s use of tabun and sarin against Iran during the Gulf War(1980-1988).  The United 
Nations delegation confirmed the use of nerve agents and other chemical warfare agents 
which caused at least 45,000 Iranian casualties.(Newmark, 2004)  During the Gulf War 
(GW-1991), a munitions dump at Khamisiyah, Iraq, was destroyed. Later, in 1996, it was 
found that the dump might have contained the organophosphate chemical warfare agents, 
sarin and cyclosarin. (Proctor, et al., 2006)  The most recent and significant deliberate use 
of sarin as nerve agent was two terrorist attacks in Japan.  The first nerve gas terrorism 
occurred at midnight on 27 June, 1994 in quiet residential area of Matsumoto. About 600 
people including residents and rescue staff were exposed to sarin gas.  Fifty-eight victims 
were admitted to hospitals and seven died.  The second attack was on 20
th
 March 1995 in 
Tokyo subway during rush –hour., that killed 12 people, 50 severely injured and 5000 
people with minor injuries.(Okudera, 2002;Yanagisawa, et al., 2006;Hoffman, et al., 
2007)    The possibility of terrorists using chemical warfare agents (CWA), particularly 
sarin is quite real.  Nerve agents are well within the capabilities of a good organic 
chemist who has access to the necessary raw materials and equipment. The nerve agents’ 
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formula and synthetic methods are relatively easily obtained from public information 
sources, including the internet.  For example, Iraqi military scientists used a U.S. patent 
that was declassified in 1975 to make VX (potent chemical warfare nerve agent).  The 
most popular example is terrorist group Aum-shinrikyo using sarin. (Leikin, et al., 2002)  
Sarin is colorless, odorless and most volatile of all the nerve agents; it makes sarin most 
likely to be used in terrorist attack.   
 
 
Sarin and its properties 
Sarin is an organophosphorus compound that contains both carbon and phosphorus 
atoms.  Sarin is basically a derivative of phosphonic (H3PO3) acid.  The biological action 
of sarin compounds is related to its phosphorylating abilities. (bou-Donia, 2003b)  
                              
Figure 1. Chemical structure of sarin (C4H10FO2P). It is also known as isopropyl 
methylphosphonofluoridate; isopropoxymethylphosphoryl fluoride and Sarin. 
   
Sarin is chemically similar to organophosphate pesticides and all exert their main 
biological effects by inhibiting acetylcholinesterase.  G-type agents (GA, Sarin, and GD) 
are clear, colorless, and tasteless liquids that are miscible in water and most organic 
solvents.  Nerve agent vapors are heavier than air and odorless.  Sarin is the most volatile 
nerve agent, evaporating at about the same rate as water.   
3 
 
Table 1. Comparison of Physical Properties of Nerve Agents          
 
(Agency for Toxic Substances and Disease Registry., 2003c) 
 
Mechanism of cholinesterase inhibition 
After exposure, sarin is primarily absorbed from the respiratory tract.  Vapors are 
absorbed through the skin at very high concentrations for G agents and at low 
concentrations of V agents. The nature and timing of symptoms following dermal contact 
with liquid nerve agents depend on exposure dose; effects may be delayed for several 
hours. (Agency for Toxic Substances and Disease Registry., 2003b)  Sarin causes 
neurotoxicity by inhibiting acetylcholinesterase (AChE).  AChE is required for 
degradation of acetylcholine (ACh).  ACh is released in response to nerve stimulation and 
binds to post-synaptic acetylcholine receptors.   Its action is rapidly terminated by 
Property Tabun (GA) Sarin (Sarin) Soman (GD) VX 
Description Clear, colorless 
and tasteless 
liquid 
Clear, colorless, 
tasteless and 
odorless liquid 
Pure liquid is 
Clear, colorless, 
tasteless and 
odorless liquid, 
discolors with 
aging to dark 
brown 
Ambered colored, 
tasteless and 
odorless oily 
liquid 
Molecular 
Weight 
162.3 daltons  140.1 daltons 182.2 daltons 267.4 daltons 
Flash point 172.4 °F 
(78°C)  
Nonflammable 249.8°F 
(121°C) 
318.2°F (159°C) 
Solubility in 
water 
9.8 g/100 g at 
77 °F(25°C) 
Miscible 2.1 g/100g at 68 
°F (20°C) 
3 g/100 g 
(miscible below 
48.9 °F (9.4 °C)) 
Volatility 490 mg/m
3
 at 
77 °F (25°C) 
22,000 mg/m
3
 
at 77 °F (25°C) 
3,900 mg/m
3
 at 
77 °F(25°C) 
10.5 mg/m
3
 at 77 
°F (25°C) 
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hydrolysis with AChE via the serine hydroxyl in the catalytic triad of AChE.  AChE very 
quickly hydrolyzes ACh, which is a continuous process.  Sarin inhibits AChE by 
phosphorylating the serine hydroxyl group at the catalytic triad site.  The phosphonic acid 
ester formed with the enzyme is extremely stable and is hydrolyzed very slowly.  The 
neurotransmitter ACh continues to elicit a response from the post-synaptic nerve, causing 
acute and chronic toxic effects. (bou-Donia, 2003a;Hoskins, et al., 1986;Wang, et al., 
2008) 
                        
Figure 2. The 3-dimensional structure of AChE  
It has an active center located at the base of a narrow gorge about 20 Å in depth.  The 
active center includes the following sites (a) the catalytic triad: Glu 334, His 447, and Ser 
203; (b) an acyl pocket Phe 295 and Phe 297; (c) a choline subunit: Trp 86,Glu 202, and 
Tyr 337; and (d) a peripheral site: Trp 286,Tyr 72, Tyr 124, and Asp 74. 
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          Organophosphorus esters inhibit AChE by phosphorylating the serine hydroxyl 
group at the catalytic triad site.  Phosphorylated AChE undergoes aging—a process that 
involves the loss of an alkyl group, resulting in a negatively charged monoalkyl enzyme. 
 
Sarin effects and excitotoxicity 
Sarin causes rhinorrhea and tightness in the throat or chest within seconds to minutes 
after exposure. (Agency for Toxic Substances and Disease Registry., 2003a)  Sarin 
causes death due to anoxia, weakness of the muscles of respiration, convulsions and 
respiratory failure.  The main clinical symptoms of acute toxicity by sarin are seizures, 
tremors and hypothermia. (bu-Qare and bou-Donia, 2002)  A study conducted on GW 
veterans concludes that, sarin and cyclosarin exposure in Iraq was significantly associated 
with less proficient neurobehavioral functioning on tasks involving fine psychomotor 
dexterity and visuospatial abilities 4–5 years after exposure.  The study also suggested a 
dose–response association between low-level exposure to sarin and cyclosarin and 
specific functional central nervous system effects 4–5 years after exposure. (Proctor, et 
al., 2006)  Convulsions are a major sign of OP poisoning of the CNS and OP-induced 
seizures rapidly leads to structural brain damage.  Convulsant doses of soman produce 
neuropathology in rats and guinea pigs.  Understanding the mechanisms underlying the 
pathophysiology of OP-induced neurotoxicity is a crucial step for the development of 
effective pharmacological antidotes for long-term effects. (Lemercier, et al., 1983;Filliat, 
et al., 1999;Taysse, et al., 2006)  The regions of the brain where neuronal damage is 
mostly observed are amygdala, piriform cortex, hippocampus and caudate.   
Neurodegeneration in the amygdala region of the brain is involved in seizures. (Filliat, et 
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al., 1999;Lallement, et al., 1991b)   Neuropathology is observed within 20-40 minutes 
after convulsion and leads to irreversible neuronal damage leading to long-term effects.  
A correlation has been observed between glutamate release in CA1 and CA3 regions of 
hippocampus and soman induced seizures(Lallement, et al., 1991b;Lallement, et al., 
1991a;Miller, 2005). 
          
                       Sarin exposure leads to a series of events.  It causes AChE inhibition and 
muscarinic receptor over stimulation, which leads to neuronal hyper- excitation and 
glutamate overflow.  Excessive presynaptic release of glutamate causes activation of 
NMDA postsynaptic receptors, which leads to neurodegeneration through excitotoxicity.  
Thus, antagonism of the excitotoxic mechanisms may protect the brain from the 
deleterious effects of OP nerve agents.  Ketamine is a noncompetitive NMDA receptor 
ion-channel blocker with neuroprotective and anti-epileptic properties, used for general 
anesthesia.  It is also.  However, it has shown high incidence of psychomimetic side 
effects.  The antitussive drug dextromethorphan and its active metabolite dextrorphan are 
potent NMDA receptor antagonists.  Both compounds were shown to possess anti-
excitotoxic and anti-epileptic properties, but individuals seeking its dissociative effects 
often abuse dextromethorphan. (Miller, 2005)  Several other NMDA receptor antagonists 
have been shown to exert anticonvulsant effects against nerve agent-induced seizures 
when administered as a pretreatment or as post treatment.  This antiepileptic feature of 
the NMDA receptor antagonists is fully expressed when they are administered 
concurrently with muscarinic receptor antagonists.  Thus, NMDA receptor antagonists do 
not modify the events responsible for the early phase of the seizure, but block the 
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subsequent recruitment of glutamate receptor activation and hence the maintenance of 
seizure activity.  It is important to note that NMDA receptor antagonists may have lethal 
interactive effects on respiratory function in soman-intoxicated subjects in the absence of 
muscarinic receptor antagonists.  Therefore, there is need for other alternatives for 
treatment of long-term effects. (Solberg and Belkin, 1997) 
 
Fear potentiated startle (FPS) response 
There is a correlation between neuropathology and memory impairments in Soman 
treated rats. (Filliat, et al., 1999)    Tokyo subway victims underwent the chronic decline 
of memory function after poisoning. (Nishiwaki, et al., 2001)   Pavlovian fear 
conditioning procedures are used to assess the behavioral, physiological, genetic and 
molecular correlates of learning and memory.  In the Pavlovian conditioned fear 
procedure, a neutral stimulus such as tone is paired with foot shock.  After few of these 
pairings the tone conditioned stimulus (CS) elicits a variety of behaviors, one of which is 
learned fear.  One of the prominent of these behaviors is fear-potentiated startle effect, in 
which conditioned fear is defined as elevated startle amplitude in the presence versus the 
absence of CS.  Fear potentiated startle can be measured after a single CS and shock 
pairing and can be retained over very long training to test intervals, making it ideal for 
examining long-term memory. (Falls and W, 1994;McNish, et al., 1997) 
 
  
 
Serotonin (5-HT) 1A agonists as novel treatments  
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Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter and utilized in a wide 
variety of physiological, sensorimotor and behavioral functions.  Serotonin signaling is 
mediated by 14 receptor subtypes with different properties.  The 5-HT1A subtype is one 
of the main mediators of the action of 5-HT which regulates the activity of 5-HT neurons 
via auto receptors and it regulates the function of several neurotransmitter systems via 
postsynaptic receptors.(Ogren, et al., 2008)  5-HT1A receptors are required for 
maintaining normal hippocampal functions.  A study of 5-HT1A receptor knockout mice 
suggests a role for 5-HT1A receptors in hippocampal-related symptoms such as learning 
and memory. (Sarnyai, et al., 2000)  Serotonin1A (5-HT1A) receptors are also localized 
in the frontal and parietal neocortex, olfactory bulb, cerebral cortex, thalamic and 
hypothalamic nuclei, raphe nuclei, septum, hippocampus, several nuclei of the brainstem    
Among  these  the hippocampus and cortex are susceptible to excitotoxic injury.(Nyakas, 
et al., 1997;Pompeiano, et al., 1992)   
                          The 5-HT1A receptor agonist repinotan is neuroprotective and attenuates 
spatial learning deficits following controlled cortical impact injury. This treatment 
strategy may be beneficial in memory impairments in humans following traumatic brain 
injury due to exposure to sarin. (Kline, et al., 2001;van der Staay, et al., 2008)  The 
neuroprotection is result of attenuation of the activity of both N-type Ca
2+
 channels and 
N-methyl-D-aspartic acid receptors and MAPK-mediated inhibition of a caspase 3-like 
enzyme pathway. (Adayev, et al., 1999;Harkany, et al., 2001;van der Staay, et al., 2008)   
                         Another full agonist, 8-OH-DPAT shows neurological protection after 
traumatic brain injury (TBI). The mechanism for the protective effects of 8-OH-DPAT 
after TBI is still not clear. (Kline, et al., 2004)  5-HT1A receptor agonist 8-OH-DPAT 
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has inhibited neuronal cell death in vivo and in vitro. (Adayev, et al., 1999;Oosterink, et 
al., 2003)  The OPs nerve agent exposure causes seizures that induce release of 
glutamate.  Glutamate causes excitotoxicity and leads to neurotoxicity.  One of the 
hypothesized mechanisms is inhibition of glutamate release by activation of 5-HT1A 
receptors.  (McDonough, Jr. and Shih, 1993;Srkalovic, et al., 1994)   Additionally, 
several full and partial 5-HT1A receptor agonists have been developed, generally with 
lower selectivity than 8-OH-DPAT.  A current approach aims to counteract the increased 
glutamatergic and cholinergic neurotransmission occurring in sarin neurotoxicity.  The 
physiological mechanisms underlying the neuromodulatory functions of 5-HT1A 
receptors are presently not well characterized.  We tested 8-OH-DPAT as a 
neuroprotectant against sarin poisoning. (Ogren, et al., 2008) 
 
Use of CBDP  
Rodents have a high amount of carboxylesterase enzyme compared to humans.  
Carboxylesterase is a chemical scavenger that inactivates organophosphate nerve agents 
among other things.  This makes rodents relatively insensitive to the toxic effects of 
organophosphorus compounds.  There will be differences in the neurotoxicity produced 
by single dose of sarin in rodents in comparison to humans.  So we propose to use CBDP 
(2-/o-cresyl/4H: 1: 3: 2-benzodioxaphosphorin-2-oxide) which is a carboxylesterase 
inhibitor. Subcutaneous CBDP has reduced LD 50 range of soman across species from 
22.8 to 125 µg/kg to 11.8 to 15.6 µg/kg. (Clement and Erhardt, 1990;Maxwell, et al., 
1987)  Doses of CBDP between 1.0 to 2.0mg/kg should prove useful as pretreatment in 
OPs induced neurotoxicity in rat, it makes mouse model comparable to actual human 
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exposure. (Jimmerson, et al., 1989)   Preliminary work has shown that an optimum dose 
of 1.5 mg/kg CBDP specifically blocks carboxylesterase, and potentiates the response of 
C57BL/6 mice to sarin.  This dose of CBDP does not inhibit AChE and produce toxic 
effects of its own. 
 
Hypothesis 
We tested the hypothesis that the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-n-
propylamino) tetralin) will work as a neuroprotectant against sarin poisoning.  The toxic 
challenge (TC) was the dose of sarin with CBDP yielding 25-50% mortality in the group.  
That gave enough number of survivors with seizure and neurodegeneration for reliable 
baselines.  We determined the neuroprotective dose response curve for   8-OH-DPAT 
against the toxic challenge.  Then, we determined time response curve of the best dose of 
5-HT1A agonist based on neuroprotection.  Finally, we tested the correlary hypothesis 
that a selected dose will prevent from memory deficits. 
 
Specific Aim 1   
Test the hypothesis that best dose of 8-OH-DPAT can act as a neuroprotectant for 
neurotoxicity produced by sarin induced convulsions in a dose dependant manner.  
Measurements were mortality, weight loss and FOB compared to control and toxic 
challenge mice.  This was used to select best dose for subsequent studies. 
 
 
Specific Aim 2  
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Test the hypothesis that best dose of 8-OH-DPAT can act as a neuroprotectant for 
neurotoxicity produced by sarin induced convulsions in a time dependant manner.  
Measurement were mortality, weight loss, FOB, ChE activity and histology compared to 
control and toxic challenge mice  
 
Specific Aim 3 
The ability of the combination of 8-OH-DPAT agonist dose of best dose and selected 
time after toxic challenge was tested for its ability to reinstate Fear potentiated startle 
(FPS) response. 
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Research design 
 
Animals 
The subjects were C57BL/6 male mice at 20-25 g body weight.  They were housed in an 
AAALAC (Association for the Assessment and Accreditation of Laboratory Animal care) 
approved facility on a 12hr light/dark cycle with free access to food and water.  All of our 
previous studies have been with this strain.  Before administration of drugs animals were 
kept 1 week in house cage so they could acclimate to the environment and handled for 3 
days to eliminate signs of stress.  Studies in mice have demonstrated interstrain 
differences both in neurochemical measures and in cognitive abilities.  A C57BL/6J 
mouse has good learning abilities and memory trace retention (at 10 days) in a simplified 
Morris maze. (Bel'nik, et al., 2009) 
 
Drugs 
We used diluted sarin (Aberdeen Proving Ground, MD) from the stock of 1.9 mg/ml 
saline solution.  It was injected in a volume of 1 ml/200g weight for each dose. Mice 
received 0.5ml/a00g body weight, for a dose of 1.5 mg/kg CBDP (a generous gift of R.A. 
Donald M.Maxwell, Pharmacology Division, United States Army Medical Institute of 
Chemical Defense, Aberdeen Proving Ground, Maryland 21010-5425, USA). We diluted 
CBDP to 0.3mg/ml in a 10% ethanol and propylene glycol solution for the dose of 
1.5mg/kg.    Sarin and CBDP injections are subcutaneous.  Our previous work established 
1.5mg/kg CBDP as the optimum dose for carboxylesterase inhibition and it does not 
interfere with cholinesterase activity.  Sarin was injected 1 hour after CBDP injection to 
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allow inhibition of carboxylesterase.  8-OH-DPAT doses of 0.3,1, 1.7 and 3 mg/ml were 
selected for dose response curve.  8-OH-DPAT was dissolved and diluted in saline for 
volume of 1ml/200g weight for each dose.  Doses of 8-OH-DPAT were given 1 minute 
after Sarin injection for dose response curve.  For the time response curve best selected 
dose (1 mg/kg) was given at different time points 1,15,30,45,60 min and 2,4,6 hours after 
toxic challenge. 
 
Weight Loss 
There was observed correlation between organophosphate nerve agent produced 
neurotoxicity and weight loss in mice. (Filliat, et al., 2007)  In our previous work, we 
observed that toxic challenge dose causes weight loss in mice.  We measured percentage 
body weight loss of mice on the first and third day after the injections. 
 
Functional Observational Battery (FOB) 
FOB contains end points that provides information of general health of mice.  It also 
provides data needed for analysis of neurotoxicity produced by neurotoxicants. (Ross J F, 
2000)  We  used a modified FOB which was used for ChE inhibitor pesticides.(Moser, 
1995;Shih and Romano, 1988)  Mice were observed for a Functional Observational 
Battery for 1-hour post Sarin dosing.  The FOB scores were taken 15, 30, 45 and 60 min 
after the sarin dose.  The FOB is based on 5 criteria with a total low score of 6 and a high 
score of 21.  It includes measures of posture, motor behavior, gait, breathing and eye 
closure.  Data is presented as percent of maximum score.   
Table 2. Functional observation battery scoring 
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Posture 
⁯ normal     ⁯ flattened   ⁯prostration ⁯ side/contorted 
Motor 
behavior 
⁯ normal    ⁯ tail twitching 
⁯ hypo-loco 
⁯ tremors ⁯ convulsions 
Gait score ⁯normal 
    
⁯ staggering 
⁯ splayed 
⁯ severe 
staggering 
⁯ unable to move 
Eyelid ⁯open ⁯ half closed ⁯ slight 
protrusion 
⁯ severe protrusion 
Breathing ⁯ normal ⁯ fast shallow ⁯ slow labored 
 
 
Blood and brain cholinesterase (ChE) activity 
We used modified version of the colorimetric assay of acetyl cholinesterase on Packard 
Fusion
TM 
Microplate Analyzer. (ELLMAN, et al., 1961)   The mice were decapitated 
after 14 days of Sarin injection and blood were collected in heparin tubes. Two eppendorf 
tubes were prepared for each blood sample inhibited for inhibition of butrylcholinesterase 
(BChE) activity and uninhibited for total cholinesterase activity.  For inhibited tubes 5ul 
10mM iso-OMPA (tetraisoproppyl-pyrophosphoramide) and for uninhibited 5ul of 
NaPO4 pH 7.4 are incubated for 45 minutes on ice.  That allows for inhibition of BChE 
activity in inhibited tubes.  Following incubation 245 µl 0.1 M NaPO4 pH 7.4 buffers is 
added in inhibited and uninhibited tubes and mixed by inverting tubes. Than 96 well plate 
is used with triplicate sample.  Total 6 wells are used for each sample, with 140 µl 0.1 M 
NaPO4 pH 8.0, 20ul sample, 20 µl 10 mM DTNB (Dithionitrobenzoate) and 20µl 10mM 
ATCh (Acetyl choline).  The plate was transferred to the plate analyser as quickly as 
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possible.  BChE activity is then calculated by subtracting AChE activity from total ChE 
activity.  Brain cholinesterase activity determined as described above.  Brain samples are 
sonicated in 0.1 M NaPO4 pH 7.4 buffer containing 0.5 % Tween 20 with a probe 
sonicator for 5 seconds for 2-3 times.  We used Tween 20 rather than Triton X-100, 
which inhibits BChE activity. (Li, et al., 2000)   Samples were centrifuged at 13000 rpm 
for 5 minutes at 4ºC.  For inhibited sample, 1µl of iso-OMPA is added to 99µl sample 
supernatant.  Protein content of the supernatant was determined using Bradford method 
(BioRad, Inc)   
 
Neuropathology 
Fourteen days post sarin treatment, mice were lightly anesthetized with CO2 ,and 
sacrificed by decapitation and brain tissue collected for histology.  Brains were quickly 
removed and quickly frozen into isopentane for 10-12 seconds and then stored at -80°C 
until sectioning. Frozen coronal sections of 10 µm were collected using cryostat (Thermo 
Shandon series, Pittsburg, PA) and TFM (TBS, INC., Durham, NC) as freezing medium).  
The section were collected on Fisher plus slides and stored in -20°C until fixed for 
staining.  We performed immunohistochemistry using Glial fibrillary acidic protein 
(GFAP) as a marker for neurodegeneration.  GFAP is a intermediate filament (IF) protein 
that is found in astrocytes in CNS. There is correlation between neurodegeneration and 
improper GFAP regulation.  Neurodegenerative condition leads to higher expression of 
GFAP that leads to glial scarring. (Liedtke, et al., 1996)  On the first day of staining, the 
slides were taken out and let dry about 30 minutes at room temperature.  A boundary was 
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made around sections with a liquid repellent PAP pen (Daido Sangyo, Tokyo, Japan) and 
let dry about 10-15 min.  Then slides were transferred to a humid chamber which is large 
petri dish with filtered paper saturated with distill water in a plastic box covered with lid 
on top.  The slides were washed with 3 times for 5 minutes and 1 time for 10 minutes 
with 0.01 M phosphate buffer solution containing 0.1 % triton (0.01 M PBS/0.1 %TX).  
The last wash was rinsed and allowed to dry.  The slides were blocked with 10 % normal 
horse serum (10 % NHS is made by using 500µl normal horse serum in 4.5 ml of 20 mM 
TBS (Tris buffered saline) for 30 minutes.  Drain off NHS and allow PAP ring to dry.  
Primary antibody solution was prepared at 1:150 dilution of rabbit anti-GFAP (Zymed, 
South San Francisco, CA) in 0.01 M PBS/0.1 %TX to block antibody.  The slides were 
kept overnight at room temperature.  Next day primary antibody was drained off from the 
slides.  Then the slides were washed with 3 times for 5 minutes and 1 time for 10 minutes 
with 0.01 M PBS/0.1 %TX.  Following this step, all steps were performed in the dark.  
Fluorescent probe-conjugated secondary antibody solution horse anti-rabbit FITC 
(Amersham, Pittsburg, PA) at a 1:50 dilution in 0.01 M PBS/0.1 % TX were prepared 
and added to slides which are kept for 2-4 hours.  Then the slides were washed with 3 
times for 5 minutes and 1 time for 10 minutes with 0.01 M PBS.  We allowed slides to 
dry and coverslip with gel –mounting medium (Bio-meda, Foster city, CA). Slides were 
stored at 4°C. We examined slides using a Leicia microscope fitted with an Optronics 
camera.  Total cell count was done specified area. Images will be analyzed using ImageJ 
(1.41O) software.   
 
Procedure for FPS testing 
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FPS consists of pre-training, training and post training sessions.  Mice are tested in 
SM100 startle monitor system version 6.12. (Kinder Scientific, 2001, Poway, CA)  In the 
fear-potentiated startle procedure, conditioned fear is operationally defined as elevated 
startle amplitude in the presence versus absence of the stimulus that was previously 
paired with shock.  This assumes that the CS does not increase or decrease startle 
amplitude prior to Pavlovian fear conditioning.  If it does then these unconditioned 
effects on startle could exaggerate or mask subsequent conditioned fear.  For these reason 
the FPS test is administered prior to Pavlovian fear conditioning and is referred to as the 
pre-test.  After a 5 min acclimation period, they are presented with 32 startle stimuli at 
two white noise intensities in 50ms pulses at 75 & 80 db ( 8 of  each), both in the 
presence and absence of the 30 sec, 12kHz pure tone of  70dB CS.  The inter interval 
between trial is 1 min.  The training session (Pavlovian fear conditioning) consists of 5 
min. acclimation, 20 tone (CS of 29.5 sec, 12 kHz pure tone of 70dB) and 0.5 sec of 
electric shock of 0.4 mA.  Pavlovian fear conditioning is repeated for two days for total 
of 40 trials.  The inter interval between trial ranges from 1 min to 3.5 min.  The post-
training test is same as pre training test and is conducted 24 hour after Pavlovian fear 
conditioning.  Finally, the percent fear-potentiated startle is computed by dividing the 
difference score by the amplitude of startle on noise burst alone trails and multiplying by 
100 (FPS= [(tone + noise burst alone- noise burst alone)/ noise burst alone] X100.  (Falls, 
2002)  
 
Statistical analysis 
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We used using Statistica software (version 7) for statistical analysis. One-way ANOVA 
was used to test for differences among two or more independent groups. Fisher Least 
significant difference test was used to identify individual group differences. In all groups 
*=p<0.05, significant, different from toxic challenge. 
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Results 
 
Mortality rates from dose response curve for 8-OH-DPAT after TC 
       We measured the mortality rate in different groups to find if there is any effects of 
DPAT on mortality.  The lower dose DPAT group showed lower mortality rate.  The 
highest dose of DPAT (3 mg/kg) increased the lethality of the TC (Table 3).  
Dose N deaths Percent 
TC 9 3 33.33% 
0.3mg/kg 8 2 25.00% 
1mg/kg 12 3 25.00% 
1.7mg/kg 9 4 44.44% 
3mg/kg 6 5 83.33% 
 
Table 3 Mortality rates comparison of different doses of 8-OH-DPAT given 1 min. after 
toxic challenge (TC).  TC was 1.5 mg/kg of CBDP and 32 µg/kg dose of sarin. 
 
 
Weight loss from dose response curve for 8-OH-DPAT after TC 
         To find out correlation of neurotoxicity and weigh loss we measured weight loss up 
to 3 days post sarin injections.  Mean percentage weight loss at day1 and day3 after 
injection, comparison of different doses of 8-OH-DPAT given 1 minute. after toxic 
challenge (TC) was measured.  TC was 1.5 mg/kg of CBDP and 32 µg/kg dose of sarin.  
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At day 1, there was greater weight loss in 0.3 and 1.7 mg/kg dose of 8-OH-DPAT group 
compared to TC group.  The weight loss of 1 mg/kg dose group was lower than TC 
group. (F3, 27 =7.2907, p<0.05)   A one way ANOVA showed significant difference of 
weight loss of 0.3 and 1.7 mg/kg dose of 8-OH-DPAT group compared to TC group.  At 
day 3, there was no significant difference in the weight loss of any of the group, but 1 
mg/kg dose group did not lose weight as much as TC group.  The two doses 0.3 and 1.7 
mg/kg showed almost similar weight loss compared to toxic challenge. Based on weight 
loss and mortality rates we selected 1mg/kg dose for subsequent studies. (Figure. 3) 
 
 
Figure. 3 mean percentage weight loss on day 1 and 3 of of different doses of DPAT 
groups compared to toxic challenge group. 
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      The mortality rate of the 1 mg/kg DPAT group was lower than toxic challenge.  The 
weight loss at day 1 and 3 was also lower than TC group.  Based on these results we 
chose 1mg/kg dose of DPAT for time response curve.  The mortality rate of 1, 15 and 30 
min 8-OH-DPAT group is not higher than TC group, but 45 and 60 min 8-OH-
DPATgroup is higher than TC group.  (Table 4)  The 2 hour and 4 hour DPAT groups’ 
toxic challenge was 1.5mg/kg of CBDP and 1 hour later 40ug/kg dose of sarin.  The 4 
hour DPAT group mortality rate was higher than toxic challenge group.  (Table 5)  The 6 
DPAT group toxic challenges were 1.5mg/kg of CBDP and 1 hour later 42ug/kg of sarin.  
The 6 hour DPAT group mortality rate was higher than toxic challenge group.  DPAT did 
not have any effects on mortality rates as some of the mice died before DPAT injections.  
(Table 6) 
 
Dose N deaths Percent 
TC 9 3 33.33% 
1 min DPAT 12 3 25.00% 
15 min DPAT 10 2 20.00% 
30 min DPAT 6 2 33.33% 
45 min DPAT 8 3 37.50% 
60 min DPAT 12 7 58.33% 
 
Table 4. Mortality rates of 1 mg/kg DPAT at various time points post toxic challenge 
(TC) injections compared to TC.  
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Dose N deaths Percent 
TC 6 2 33.33% 
2hr DPAT 9 3 33.33% 
4hr DPAT 10 6 60.00% 
 
Table 5. Mortality rates of 2 and 4 hour DPAT groups post toxic challenge (TC) 
injections compared to TC.  
 
Dose N deaths Percent 
TC 5 2 40.00% 
6hr DPAT 11 5 45.45% 
 
Table 6. Mortality rates of 6 hour DPAT group post toxic challenge (TC) injections 
compared to TC 
 
 
Weight loss from time response curve for 8-OH-DPAT 
               Mean percentage weight loss at day1 and day 3 comparisons of vehicle control, 
DPAT control, toxic challenge (TC) and 1mg/kg of 8-OH-DPAT given after TC at 
different time points was performed.   The control group received propylene glycol and 
1-hour later saline.  DPAT control group received 1 mg/kg dose of 8-OH-DPAT.  At day 
1, there was higher weight loss in 8-OH-DPAT group of 15, 30, 45 and 60 min than toxic 
challenge group.  There was lower weight loss in 1 min 8-OH-DPAT group.  There was 
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no significant difference of weight loss between TC and 8-OH-DPAT group at different 
time points at day 1.  One-way ANOVA showed significant difference between control 
group and TC, 15, 30, 45, 60-minute 8-OH-DPAT group. (F7, 53=6.2234, p<0.0001)  At 
day 3, there was higher weight loss in 60 min 8-OH-DPAT group than toxic challenge 
group.  At day 3, there was lower weight loss in 8-OH-DPAT group 1, 15, 30 and 45 min 
compared to TC group.  There was no significant difference between of weight loss 
between TC and 8-OH-DPAT group at different time points at day 3.  One way ANOVA 
showed significant difference between control group and TC, 15, 45, 60 minute 8-OH-
DPAT group.  (F7, 51=5.2500, p<0.001) (Figure 4)   There is higher weight loss on day 1 
and 3 of 2 hour DPAT group compared to toxic challenge. (Figure 5)  There is lower 
weight loss in 6 hour DPAT group compared to toxic challenge at both day 1 and 3. 
(Figure 6) 
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Figure 4. Mean percentage weight loss on day 1 and 3 of DPAT group compared to toxic 
challenge group. 
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Figure 5. Mean percentage weight loss on day 1 and 3 of 2 and 4 hour DPAT groups 
compared to toxic challenge group. 
 
 
Figure 6. Mean percentage weight loss on day 1 and 3 of 6 4 hour DPAT group compared 
to toxic challenge group. 
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Functional observational battery scores from time response curve for 8-
OH-DPAT 
                 All groups injected with Sarin showed signs of poisoning and mortality.  This 
is required in groups for brain pathology.  Functional Observational Battery scores were 
calculated for animals injected with the vehicle control, DPAT control, TC and TC+ 
DPAT at different time points thereafter.  A one way ANOVA performed on percentage 
of maximum score showed significant differences between control and Sarin treated 
groups. (F7, 65=54.520, p<0.0001)  (Figure 7)  For 2, 4 and 6 hour DPAT groups FOB 
scores were measured at longer time points until 24 hours.  At 24 hours 2 and 4 hours 
FOB scores are lower than toxic challenge group.  (Figure 8)  FOB score of 6 hour DPAT 
group is higher than toxic challenge at 24 hours. (Figure 9)   
 
Figure 7.  Percentage FOB scores of DPAT, vehicle control groups to toxic challenge 
group. 
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Figure 8. Mean percentage FOB scores of 2, 4 hour DPAT groups compared to toxic 
challenge at different time points. 
 
 
Figure 9. Mean percentage FOB scores of 6 DPAT group compared to toxic challenge at 
different time points. 
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Blood ChE and AChE activity 
     The blood ChE and AChE activity was measured 14 days post injection.  The ChE 
activity was measured on trunk blood collected by decapitation.  There is no significant 
difference of ChE activity between any of the groups.  There is also no significant 
difference between AChE activities between any of the groups (Figure 10) 
 
 
Figure 10. Blood ChE activity of different groups 14 days post Sarin injection. 
Frontal cortex AChE activity 
      The frontal cortex ChE and AChE activity was measured 14 days after injection.  
Mice were euthanized using CO2 and decapitated.  The ChE activity in all 8-OH-DPAT 
groups after15 min was lower than the toxic challenge group.  (Figure 11) 
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Figure 11. Frontal cortex ChE and AChE activity in DPAT groups compared to TC group 
 
 
GFAP cells counts in dentate gyrus from time response curve for 8-OH-
DPAT 
            Glial fibrillary acidic protein (GFAP) is a marker for neurodegeneration, which is 
highly responsive to neuronal damage.  An increase in GFAP is an indication of trauma 
to these cells.  GFAP cell counts was conducted in dentate gyrus of hippocampus for 
animals injected with the vehicle control, DPAT control, TC and 1 mg/kg DPAT at 
various time points post TC injections at 14 days post injection. We observed significant 
differences of GFAP cells in dentate gyrus of hippocampus in up to 2 hour time points 
compared to TC group, with the values the same as for background. (F7, 37=7.0575, 
p<0.0001)  (Figure 12, 13)  
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Figure 12. GFAP cells in dentate gyrus of hippocampus in different groups .   
 
Figure 13. GFAP cells in dentate gyrus of hippocampus in 2 and 4 hour DPAT groups 
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Below are images of the dentate gyrus of the hippocampus of different groups stained for 
GFAP. (Figure 14,15)  All the picture were taken on 20x magnification using  optronics 
camera using a Leica microscope.  We euthanized all the groups two weeks after 
injections. All the injections were SC. route.  The control group received propylene 
glycol and 1 hour later saline. The DPAT control group received propylene glycol, 1 hour 
later saline and 1 minute after 1 mg/kg of 8-OH-DPAT.  The toxic challenge group 
received 1.5 mg/kg of CBDP and 1 hour later 32 ug/kg of Sarin injection.   The DPAT 
groups received toxic callenge and 1mg/kg of 8-OH-DPAT at time points according to 
groups.   
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Figure 14. Dentate gyrus of hippocampus of different groups ,mouse euthanized 14 days 
after injection (a) control group dose with  propylene glycol and saline (b) toxic challenge 
group dosed with 1.5mg/kg CBDP and 32ug/kg Sarin (c) DPAT control group dosed with 
propylene glycol, saline and 1mg/kg 8-OH-DPAT (d) 1 min DPAT group dosed with 
toxic challenge and 1 minute later 1m/kg 8-OH-DPAT 
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Figure 15 Dentate gyrus of hippocampus of  time points of DPAT groups, 1mg/kg DPAT 
given after toxic challenge at (a) 15 min (b) 30 min (c) 45 min (d) 60 min  
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Fear potentiated startle (FPS) response 
               We performed fear potentiated startle response test on three groups control, 
toxic challenge and 45 min DPAT group.    Mice were assigned into groups according to 
averages of their startle amplitude.  All injections were S.C. route.  The control group 
received propylene glycol and 1-hour later saline. The toxic challenge group received 1.5 
mg/kg CBDP and 1-hour later 42ug/kg of Sarin.  The DPAT group received toxic 
challenge and 45 minute later 1mg/kg of 8-OH-DPAT.  Three weeks after injections mice 
were fear conditioned for Pavlovian fear conditioning the training session which consists 
of 5 min. acclimation, 20 tone (CS of 29.5 sec, 12 kHz pure tone of 70dB) and 0.5 sec of 
electric shock of 0.4 mA.  Pavlovian fear conditioning was repeated for two days for 40 
trials.  24 hours later mice were tested for posttest, which is same as pre test.  At 75, 80 
db white noise and average FPS TC group learned the conditioning.  We previously 
preformed three weeks FPS studies on asymptomatic doses of Sarin (0.4 LD50) and the 
Sarin group did not learn.  In our experiment the symptomatic dose of Sarin group 
learned and left our test inconclusive. 
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Figure 16. Fear potentiated startle at 75 db white noise 
 
Figure 17. Fear potentiated startle at 80 db white noise of different groups. 
 
Figure 18. Average Fear potentiated startle of 75 and 80db white noise of different 
groups. 
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                The FPS control mice were treated with propylene glycol and saline.  The TC 
group received 1.5mg/kg CBDP and 42ug/kg Sarin.  The DPAT group was injected 
1.5mg/kg CBDP and 42ug/kg Sarin and 45 minutes later 1 mg/kg of 8-OH-DPAT.  Mice 
were euthanized 4 weeks after injection.  Immunohistochemistry was performed on 
frozen sections and GFAP cells in dentate gyrus region were calculated.  GFAP cell were 
significantly lower in dentate gyrus of hippocampus in control and 45 min DPAT group 
compared to TC group. (F2, 24=82.174, p<0.0001) (Figure 19) 
 
Figure 19.   GFAP cells in dentate gyrus of hippocampus in different groups. 
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Discussion 
                The main objective of the study was to look for novel neuroprotectants for 
treatment of long-term effects produced by sarin induced convulsions.   This required 
identification of the dose of sarin that will produce a mortality rate with enough survivors 
for reliable baseline.  We also wanted to make our model comparable to actual human 
exposure.  We used CBDP with sarin to inhibit the high levels of carboxylesterase seen in 
rodents to reduce the total sarin dose and thus to make the mouse model closer to 
humans.  We tested the 5-HT-1A agonist 8-OH-DPAT for treatment of sarin and CBDP 
induced convulsions.  We performed dose response and time response curves for 8-OH-
DPAT and looked at the parameters of mortality rates, weight loss, FOB, blood and brain 
cholinesterase activity, immunohistochemistry for degenerating neurons and FPS.  We 
observed neuroprotection by DPAT in the dentate gyrus of hippocampus up to 2 hours 
after the administration of the toxin.  We also tested other 5-HT-1A agonists in our 
laboratory but they were ineffective.  The mechanism of the neuroprotection produced by 
DPAT is still not clear.  We observed that 8-OH-DPAT influenced on the pattern, 
intensity, and duration of sarin-induced seizures using ECoG; this mechanism could 
underlie the neuroprotection produced by 8-OH-DPAT in dentate gyrus of hippocampus. 
Use of Sarin and CBDP 
              Carboxylesterase are important in the detoxification of a number of 
organophosphorus insecticides.  Humans have low carboxyl esterase in blood and tissue 
in comparison of rodents. (Pope, et al., 2005)   Rodents will require higher doses of sarin 
to produce its effects.  Administration of CBDP significantly reduced the dose of sarin 
necessary to produce symptoms. Administration of CBDP potentiated Sarin almost five 
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times from 200ug/kg to 42ug/kg to produce 25-50 % mortality rates.  Carboxylesterase is 
important detoxifier of sarin.  The administration of this dose of CBDP specifically 
blocks CaE; therefore less Sarin dose was required to produce its effects.  The CBDP and 
Sarin injection were separated by 1 hour.  At the time of Sarin administration carboxyl 
esterase was blocked by CBDP.  The lower dose of Sarin irreversibly blocked 
cholinesterase and produced toxic effects.    CBDP administration reduced our Sarin dose 
from a range of 160-200 ug/kg to 32- 42 ug/kg., while even repeated low level sarin 
exposure of  64 ug/kg is asymptomatic. (Jimmerson, et al., 1989) CBDP dose of 2 mg/kg 
or higher significantly lowers cholinesterase activity in blood and brain.(Mach, et al., 
2008)  We used 1.5 mg/kg of CBDP which did not interfere with cholinesterase activity, 
making our model closer to actual human exposure.  
 
Dose response curve of 8-OH-DPAT 
            We determined the neuroprotective dose response curve for the 5-HT-1A agonist 
8-OH-DPAT against the toxic challenge of 1.5mg/kg of CBDP and 32ug/kg of Sarin over 
the range from of 0.3, 1, 1.7 and 3 mg/kg of 8-OH-DPAT.  The 5-HT1A receptor is the 
most studied and best characterized 5-HT receptor subtype to date.  5-HT1A receptors are 
abundantly expressed in cortical and hippocampal (CA1/CA3 and dentate gyrus) regions 
that are critically involved in learning and memory and susceptible to neuronal damage. 
(Kline, et al., 2007)  5-HT1A receptor involvement in modulation of the major 
neurotransmitters ACh, DA, and glutamate, the serotonin (5-HT) system, is considered a 
significant pharmacological target for the treatment of various central nervous system 
(CNS) diseases.  Administration of 5-HT1A receptor agonists before or after focal 
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cerebral ischemia provides neuroprotection as evidenced by decreased histopathology.  
Single administration 5-HT1A receptor agonist of 8-OH-DPAT decreases cortical lesion 
volume and hippocampal neuron survival.  Single systemic administration of the 5-HT1A 
receptor agonist 8-OH-DPAT enhances behavioral recovery after experimental traumatic 
brain injury (TBI). Intraperitoneal administration of 0.5 mg/kg dose of 8-OH-DPAT 
confers neurological protection after TBI in Hippocampal CA1/CA3 region. (Cheng, et 
al., 2008; Kline, et al., 2004)  8-OH-DPAT is much more potent when injected 
subcutaneously than when injected Intraperitoneal, the potency difference being 
approximately 17-fold. (Fuller and Snoddy, 1987)  The important influence of route of 
administration on the potency of 8-OH-DPAT must be considered in interpreting the 
various functional effects that have been reported with it.  After oral administration, 8-
OH-DPAT goes first-pass metabolism and shows low oral bioavailability of, rather than 
poor absorption from the GI tract. (Mason, et al., 1995)  We selected doses of in range of 
0.3 to 1.7 mg/kg of 8-OH-DPAT for subcutaneous administration for our dose response 
curve.  The mortality rate for our toxic challenge group is 33.33 %.  The lower dose 
group 0.3 and 1 mg/kg of 8-OH-DPAT showed less mortality than toxic challenge but 
mortality increased with higher doses of 1.7 and 3 mg/kg.  8-OH-DPAT is not a rescue 
drug for treatment of nerve agent exposure therefore; we did not see any significant 
effects on mortality rate.  The reason for higher mortality rate in higher doses of DPAT 
groups is still not clear.  There could be unknown interaction between higher doses of 
DPAT with CBDP or Sarin causing higher mortality.   
                      We measured total body weight loss on mice up to 3 days post sarin 
injections.  Body weight is related to general health status, periodic measurement can 
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indicate if animals are recovering or still in poor health.  Knowledge of body weight is 
crucial for neurotoxicity testing.  Body weight loss can be an indicator of neurotoxin 
effects on CNS.  Rats treated with artelinic acid showed signs of neurotoxicity and 
significantly lost weight.  (Si, et al., 2007)  At day, 1 0.3 and 1.7 mg/kg DPAT group 
showed higher weight loss compared to toxic challenge group.  Only one mouse survived 
in 3mg/kg group after injection.  We did not include that group in our results due to low 
number in the group.  At both day 1 and 3, 1 mg/kg the DPAT group weight loss was 
lower than the toxic challenge group, while at day 3 other doses had higher weight loss.  
We selected as the best dose 1mg/kg of 8-OH-DPAT for the time response curve with 
toxic challenge based on lower mortality and lower weight loss data.  
 
Time response of 1 mg/kg of 8-OH-DPAT with toxic challenge  
                We performed a time response of 8-OH-DPAT with the 1mg/kg selected dose 
from the dose response curve.  We gave DPAT at 1, 15, 30, 45, 60 minutes 2, 4 and 6 
hour after toxic challenge.  Weight loss of mice treated with DPAT 1 and 15 min after 
toxic challenge was lower than TC group.   At later time points in DPAT group the 
morality was similar or higher than toxic challenge group.  Since DPAT is not a rescue 
drug it does not reduce the mortality rate in the Sarin treated animals.  That there were no 
significant differences in lethality between DPAT groups suggests that it was without 
major effect.  The small difference in the mortality rate could be due to inter individual 
differences in susceptibility of animals to Sarin treatment.  We measured total body 
weight loss up to 3 days in all DPAT groups. Only the 1-minute DPAT group had lower 
weight loss than toxic challenge at both 1 and 3 days.  None of the DPAT group has 
41 
 
significantly lower weight loss than toxic challenge group.  Lower food and water intake 
could be the reason of weight loss after Sarin injection after 3 days.   
                  Mice were observed using a Functional Observational Battery for 1-hour post 
Sarin dosing.  As neurobehavioral assessments during the preliminary stages of chemical 
testing are important, it is critical that the screening procedures utilized be valid 
indicators of neurobehavioral function and that they be sensitive, specific, and reliable.  
In many instances, the effects observed with the FOB may be predictive of 
symptomology in humans and comparisons can be made between effects detected with 
the FOB and other methods of measuring neurotoxicity. (Moser, 1990;Si, et al., 2007)  
We observed higher FOB scores in all Sarin treated groups.  There were no significant 
differences between any of the Sarin treated groups.  We observed a significant 
difference in FOB scores between vehicle control and Sarin treated groups.  We only 
measured 1 hour time point FOB score post injection and observed no difference in 
groups, so we concluded that animals do not recover from acute symptoms if they are not 
treated with rescue therapy.  We decided to monitor FOB scores for 24 hours in 2, 4 and 
6-hour DPAT groups.  We did not observe any significant difference in FOB score 
between toxic challenge and DPAT groups in any time points.  It confirms DPAT is not a 
rescue drug and it does not have any effects on acute effects produce by neurotoxicity of 
sarin dose.   
                            We also measured blood and brain cholinesterase activity 14 days post 
injections in groups.  Acute symptoms of sarin are produced by irreversible inhibition of 
the cholinesterase enzymes.   CBDP alone does not produce any effects on total ChE 
levels.  We have previously determined in our laboratory that toxic challenge doses of 
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Sarin significantly reduce blood cholinesterase activity compared to control group 
animals 4 days post injections.   We observed no significant difference in blood ChE and 
AChE in any of the groups 14 days after treatment.  However, new red blood cell 
production rapidly restores blood AChE levels and the BuChE in plasma is available 
from the liver. Frontal cortex ChE activity was lower in DPAT groups than the toxic 
challenge group.  It is not clear why this occurred as DPAT neither inhibits nor 
regenerates AChE (Mason, 2000)  Thus, DPAT is not providing neuroprotection by 
reducing in acute symptoms, restoring the animal’s general health more rapidly or by 
regenerating AChE. 
 
Neuroprotection by 8-OH-DPAT         
                 Sarin exposure leads to neuronal damage, which includes cell degeneration in 
specific areas like the hippocampus, the piriform cortex and the thalamus. This damage 
might expand with time to include additional brain areas.  Soman exposure causes cell 
death in mice, in which damaged neurons continue to be present in hippocampal CA1 up 
to 90 days post soman exposure.  GFAP staining was evident in dentate gyrus of soman 
exposed mice, the GFAP staining consistently increased until 15
th
 days post exposure.  
The cascade of events induces long-term effects.   Inhalation of sarin vapors induced 
impaired memory processes seen at 1-month post exposure with no recovery of function 
during the 6 months follow-up period. Similarly, long-term follow-up of victims of the 
sarin attacks in Japan demonstrated neurological as well as emotional and cognitive 
changes up to 7 years post exposure. (Collombet, et al., 2007;Grauer, et al., 2008)  Long-
term impaired neurobehavioral functioning effects were also recently reported following 
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low-dose inhalation exposure to sarin and cyclosarin during the 1991 Gulf War. An 
appropriate treatment might halt the damaging processes and may even allow for 
functional recovery.  Current treatment therapies include atropine and 2-PAM, which are 
rescue therapy for acute toxicity.  Current therapy still does not protect from long term 
effects.  We found neuroprotection in dentate gyrus of hippocampus with 1mg/kg dose of 
8-OH-DPAT.  The neuroprotection was significant up to 2 hour DPAT injection after 
exposure to sarin.  The groups were euthanized 14 days post injections it shows that toxic 
challenge mice groups are still showing signs of neurodegeneration.  The four-hour 
DPAT group GFAP cell count is lower than toxic challenge but is not significant that 
shows DPAT is not effective post 2 hour as treatment. (Collombet, et al., 2007;Grauer, et 
al., 2008) Initiation and early expression of the seizures are cholinergic phenomenon; 
anticholinergics readily terminate seizures at this stage and no neuropathology is evident. 
However, if not treated, a transition phase occurs during which the neuronal excitation 
leads to neuropathology, where Control with anticholinergics becomes ineffective.  With 
prolonged epileptic form activity the seizure enters a predominantly non-cholinergic 
phase, 5-HT-1A may work as a neuroprotectant.  Since DPAT is neuroprotective up to 2 
hour it can be given to a patient who does not receive timely rescue therapy to prevent 
long term effects. (McDonough, Jr. and Shih, 1993)  In another study in our laboratory, 
we tested the hypothesis that the neuroprotective effects of 8-OH-DPAT against sarin-
induced neuropathology resulted from alteration of the seizure pattern.  Swiss Webster 
mice were implanted subcutaneously (sc) with transmitters and cortical electrodes for 
telemetry recordings.  Recordings of baseline electroencephalography (EEG) were 
obtained and mice were then injected with 200 µg/kg (sc) of Sarin and EEG recordings 
44 
 
were taken for 4 hours unless death resulted.  A second group was dosed with 200 µg/kg 
of Sarin and 1 min later DPAT (1.0 mg/kg) (sc).  All of the sarin dosed mice exhibited 
behavioral signs of seizure activity.  The recordings substantiated that seizures occurred 
and they continued increasing in severity of spikes. There was a significant difference in 
the seizure activity of mice dosed with sarin alone compared to the mice with 
sarin+DPAT.  The EEG of the sarin dosed mice indicated both high frequency and 
amplitude seizure patterns.  The seizure pattern of the sarin+DPAT dosed mice revealed 
seizure patterns with greater intervals between spikes, lower spike amplitudes, and fewer 
spike trains. (Table 6) (Figure 20, 21)  These studies demonstrate that 8-OH-DPAT 
influences the pattern, intensity, and duration of sarin-induced seizures in mice. 
(unpublished versions of work done by Belinda Sims)  
 
             
 
Figure20:  30 second baseline recording of cortical EEG of control Swiss Webster mouse.   
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Figure 21. 30 second seizure recording of cortical EEG.  Swiss Webster mouse dosed 
with 200µg/kg of Sarin, 3 hrs post injection.  Green marker shows 28 second spike train 
and the red dotted lines indicate baseline amplitude threshold.  
 
 
Figure 22. 30 second seizure recording of cortical EEG.  Swiss Webster mouse dosed 
with 200µg/kg of Sarin and 1.0 mg/kg DPAT (1 min post Sarin), 3 hrs post injection.  
Green markers show 3 second spike trains, red dotted lines indicate baseline amplitude 
threshold.  
 
 
Group 3 hr, Mean 
Spike 
Train 
Duration, 
(seconds) 
Total number 
of spike 
trains 
 
Inter Spike 
Train 
Mean  
(seconds) 
Amplitude 
3 hrs post 
injection 
(µV) 
 
 Sarin ALONE 3.7±1.4 
 
785±293 0.26±0.03 0.91± 0.24 
 
 
Sarin + DPAT 3.4±0.3 185±25 
 
 
0.43±0.06 
 
 
0.21 ± 0.08 
 
 
 
Table 6.  EEG data of Sarin group compared to DPAT group. 
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8-OH-DPAT and emotional learning 
            Sarin exposure causes memory impairment in rodents and humans. We tested the 
ability of the 8-OH-DPAT agonist dose of 1mg/kg and 45 minute after toxic challenge for 
its ability to reinstate Fear potentiated startle (FPS) response.  We have previously 
determined in our laboratory that two low doses sarin to mice produces impairment of 
acquisition of fear-potentiated startle response.  We assumed that our doses Sarin with 
CBDP would produce impairment in acquisition of startle response.  On the contrary, our 
toxic challenge group learned the conditioning.  This result negated the ability of the 
study to demonstrate the ability of 8-OH-DPAT to reverse learning deficits.  The vehicle 
control group learned the conditioning but the difference between pre and posttest was 
not significant, as we have previously determined.  The results show that our dose was on 
the breaking point between interference at low doses and noninterference at higher doses. 
 
Conclusion 
           We were able to utilize CBDP rodents to more accurately model actual human 
exposure.  CBDP reduced the dose of Sarin which produces 25-50 % mortality in mice.  
This model helps to reduce variability produce by single actual dose of Sarin.   We also 
observed significant neurodegeneration in dentate gyrus of hippocampus in toxic 
challenge group.  These results are consistent, repeatable and similar to our previous 
laboratory experiments.  We were able to produce neuroprotection with the 1mg/kg dose 
of the 5-HT-1A agonist 8-OH-DPAT.  8-OH-DPAT was able to produce neuroprotection 
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up to 2 hours post toxic challenge.  DPAT did not produce any effects on mortality rate, 
weight loss or ChE activity.  8-OH-DPAT does not produce any effects on cholinesterase 
inhibition.  Our laboratory observed that 8-OH-DPAT influences the pattern, intensity, 
and duration of sarin-induced seizures in a fashion that could account for the observed 
neuroprotection in the dentate gyrus of hippocampus.  We suggest that the efficacy of 8-
OH-DPAT treatment lies in its ability to attenuate glutamate release, thereby putting an 
end to seizure activity due to NMDA receptor stimulation. (Srkalovic, et al., 
1994;McDonough, Jr. and Shih, 1993)  We have also tested other 5-HT-1A agonists in 
our laboratory post toxic challenge injections, including buspirone and S-14506.  Both 
these compounds increased the mortality rate compare to toxic challenge group but did 
not have any effects on weight loss and FOB.  The mechanism neuroprotection of 8-OH-
DPAT is still not definitively determined.  Further work should be done to identify the 
mechanism of DPAT action.     Sarin exposure leads to long-term effects if current rescue 
therapy atropine and 2-PAM is not given to stop initial seizure activity.  Since DPAT is 
effective up to 2 hours after sarin, it may be an effective therapy for neuroprotection from 
the long-term effects produced by sarin induced convulsion.  Since DPAT does not 
protect from acute symptoms, it is not useful as rescue agent.  8-OH-DPAT may be used 
as addition to current rescue treatment of atropine and 2-PAM. 
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